| 08.30 |
Registration |
| 09.00 |
Welcome
- Robert Barnes, Global Head of Primary Markets & CEO Turquoise Global Holdings, London Stock Exchange Plc
|
| 09.05 |
Policy Keynote
- Robert Jenrick MP, The Exchequer Secretary to the Treasury, HMG
|
| 09.25 |
Markets Keynote
- James Mitford, Managing Director, JP Morgan
|
| 09.35 |
Industry Keynote - Future Innovations in Respiratory Healthcare
- Dave Allen, Head of Respiratory Therapy, GSK
|
| 09.55 |
Panel I – Investing in Innovation
- Martin Murphy, CEO, Syncona
- David Baynes, COO, IP Group
- Victor Christou, CEO, CIC
- Vishal Gulati, Partner, Draper Esprit
Chair: James Black, Numis
|
| 10.35 |
Info Shot - Reinventing the scientific method
- Jackie Hunter, CEO, Benevolent.ai
|
| 10.50 |
Coffee Break
|
| 11.20 |
Panel II – Finding Balance
- John Burt, CEO, Abzena
- Doug Doerfler, CEO, Maxcyte
- Shaun Chilton, CEO, Clinigen
- Sarah Howell, CEO, Arecor
Chair: Jo Pisani, Partner, PwC
|
| 12.00 |
Info Shot - Realising the potential of population data
- Joanne Hackett, Chief Commerical Officer, Genomics England
|
| 12.15 |
Panel III – Breath of Fresh Air
- James Ward-Lilly, Group CEO, Vectura
- Steve Harris, CEO, Circassia
- Keyvan Djamarani, Managing Director, Bespak, Consort
- Tom Keith-Roach, Vice President, Respiratory, AstraZeneca
Chair: Chris Shelley, Partner, Penningtons Manches
|
| 12.45 |
Closing Keynote - Innovating to stay ahead in rare diseases
- Peter Meeus, Head of Europe, Shire
|
| 13.00 |
Closing remarks
|
| 13.05 |
Closing Thanks
- Steve Bates, CEO, Bioindustry Association
|
|
13.10
|
Lunch |
